It is made available under a CC-BY-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.07.14.23292649;](https://doi.org/10.1101/2023.07.14.23292649) this version posted July 16, 2023. The copyright holder for this preprint

1 **Early Biological Markers of Post-Acute Sequelae of SARS-CoV-2 Infection**

- 2 **Onset Sentence Summary:** Early viral dynamics and the associated host immune responses 3 play a role in the pathogenesis of PASC.
- 4 **Authors:** Scott Lu^{1,2*}, Michael J. Peluso^{3*}, David V. Glidden², Michelle C. Davidson⁴, Kara
- 5 Lugtu¹, Jesus Pineda-Ramirez¹, Michel Tassetto⁵, Miguel Garcia-Knight⁵, Amethyst Zhang⁵,
- 6 Sarah A. Goldberg², Jessica Y. Chen², Maya Fortes-Cobby¹, Sara Park¹, Ana Martinez¹,
- 7 Matthew So¹, Aidan Donovan³, Badri Viswanathan², Rebecca Hoh,³ Kevin Donohue⁴, David R.
- 8 McIlwain⁹, Brice Gaudiliere⁹, Khamal Anglin¹, Brandon C. Yee⁶, Ahmed Chenna⁶, John W.
- 9 Minslow⁶, Christos Petropoulos⁶, Steven G. Deeks³, Melissa Briggs-Hagen⁷, Raul Andino⁵,
- 10 Claire M. Midgley⁷, Jeffrey N. Martin², Sharon Saydah^{7*}, J. Daniel Kelly^{1,2,4,8*}
- 11 *Indicates equal contribution

12 **Affiliations:**

- 13 1 Institute for Global Health Sciences, University of California, San Francisco (UCSF), San
- 14 Francisco, CA, USA;
- 15 2 Department of Epidemiology and Biostatistics, UCSF, San Francisco, CA, USA;
- 16 3 Division of HIV, Infectious Diseases, and Global Medicine, UCSF, San Francisco, CA, USA;
- 17 4 School of Medicine, UCSF, San Francisco, CA, USA;
- 18 5 Department of Microbiology and Immunology, UCSF, San Francisco, CA, USA;
- 19 6 Labcorp Monogram Biosciences, South San Francisco, CA, USA;
- 20 7 Division of Respiratory Viral Pathogens, CDC;
- 21 8 F.I. Proctor Foundation, UCSF, San Francisco, CA, USA;
- 22 9 Department of Microbiology and Immunology, Stanford, CA, USA.
- 23 Word count:

- 24 "The findings and conclusions in this report are those of the authors and do not necessarily
- 25 represent the official position of the Centers for Disease Control and Prevention"

27 **Abstract:** To understand the roles of acute phase viral dynamics and host immune responses 28 in PASC, we enrolled 136 participants within 5 days of their first positive SARS-CoV-2 real-time 29 PCR. Participants self-collected nasal specimens up to 21 times within the first 28 days after 30 symptom onset; Interviewer-administered clinical questionnaires and blood samples were 31 collected at enrollment and days 9, 14, 21, 28, and month 4 and 8 post-symptom. Defining 32 PASC as the presence of any symptom new or worse since infection reported at their 4-month 33 visit, we compared viral markers (quantity and duration of viral RNA load, infectious viral load, 34 and plasma N-antigen level) and host immune markers (IL-6, IL-10, TNF- α , IFN- α , IFN- γ , MCP, 35 IP-10, and Spike IgG) over the acute period. In comparison to those who fully recovered, those 36 who developed PASC demonstrated significantly higher maximum levels of SARS-CoV-2 RNA, 37 infectious virus, and N-antigen, longer duration of viral shedding, and lower Spike-specific IgG 38 levels within the first 10 days of the acute phase of illness. No significant differences were 39 identified among a panel of host immune markers, though there was a trend toward higher initial 40 levels of certain markers (e.g., MCP-1, IFN- α , and IFN- γ) in those who went on to develop 41 PASC. Early viral dynamics and the associated host immune responses play a role in the 42 pathogenesis of PASC. These findings highlight the importance of understanding the early 43 biological markers from acute SARS-CoV-2 infection in the natural history of PASC.

44 **Introduction**

45 Post-acute sequelae of SARS-CoV-2 infection (PASC) includes ongoing symptoms in the 46 months following acute SARS-CoV-2 infection. Estimates of the occurrence of PASC can vary, 47 currently approximately 1 in 10 U.S. adults who have had COVID-19 reporting ongoing 48 symptoms (1). Despite a growing understanding of its epidemiology and natural history, the 49 pathogenesis of PASC remains incompletely understood (2). Multiple mechanisms that could 50 contribute to this condition are now under investigation (2, 3). 51 Viral antigen persistence and immune dysregulation are two mechanisms that might drive PASC 52 (4-9). For example, recent work has suggested that a high proportion of individuals with PASC 53 demonstrate detectable SARS-CoV-2 antigen in blood plasma during the post-acute phase (4, 54 6), and subgenomic RNA has been identified in widespread tissue sites at autopsy for up to 6 55 months post-COVID (5). Furthermore, studies comparing individuals with PASC with those who 56 report complete recovery from SARS-CoV-2 infection have demonstrated increased levels of 57 certain inflammatory markers including IL-6, TNF-alpha, and IL-1B, among others, for at least a 58 year following infection (7-9). However, most work on PASC to date has been limited to the 59 study of biological samples collected during the post-acute phase of infection.

60 Biological samples for predictors of PASC from the acute and early post-acute phase are more 61 limited. Most studies from early infection have focused on shorter-term outcomes in hospitalized 62 individuals (10, 11), although more recently some studies have suggested that prolonged viral 63 clearance (12) or distinct early immune signatures (13) could be associated with PASC. While 64 informative, these studies have been limited by relatively small study populations and/or less 65 frequent biospecimen collection timepoints.

66 Here, we leveraged a household-based cohort of individuals intensively sampled during the 67 acute phase of SARS-CoV-2 infection to assess the early biological determinants of PASC. We

- 68 hypothesized that selected biological marker activity during early infection play a role in the
- 69 pathogenesis of persistent symptomatology following the acute period of illness.

70 **Methods**

71 *Study Population and Procedures*

72 This was a longitudinal cohort study enrolling individuals acutely infected with SARS-CoV-2 and 73 their household contacts in the San Francisco Bay area between September 2020 and May 74 2022. Details on the protocol and procedures for enrollment have been described in detail 75 elsewhere (14). In brief, we enrolled participants who were recently diagnosed with nucleic acid-76 confirmed SARS-CoV-2 infection within 5 days of symptom onset. Molecular testing results from 77 UCSF-affiliated sites were used by research staff to screen and recruit participants via in-person 78 and telephone interviews. A study field team visited participants in their areas of isolation a total 79 of 5 times during acute infection at the following timepoints: day of enrollment (ranging between 80 day 0 and day 5 following self-reported symptom onset), and day 9, 14, 21, and 28 following 81 symptom onset. At each study visit, blood and nasal specimens were collected. In addition, 82 participants self-collected swabs of the anterior nares for the first 14 days post-infection, and at 83 d17, 19, 21, and 28. Research coordinators administered phone interviews on the same day as 84 the field visit within the acute period, then at 4 and 8 (+/- 2 months) months post-infection, using 85 identical instruments developed in conjunction with a study of the post-acute phase (15).

86 *Measurements*

87 *Survey-based*

88 We piloted a questionnaire containing items with key sociodemographic, medical history, 89 symptomatology, quality-of-life, and later vaccination information. This instrument was 90 developed with infectious disease specialists and epidemiologists who had managed COVID-19 91 patients. The form was iteratively developed over time and continues to be developed during 92 the present study. Symptom items included a checklist of 32 selected symptoms followed by a

93 free response option. The surveys are designed to assess symptom status from the time of the 94 last interview to the current one. All symptoms reported as new, worsened or persistent since 95 SARS-CoV-2 infection were captured; presence of symptoms prior to acute COVID-19 illness 96 were assessed for exclusion from later analyses. Comorbid conditions include history of 97 autoimmune disease, cancer, diabetes, HIV/AIDS, heart disease, hypertension, lung disease, 98 and kidney disease.

99 The primary outcome of PASC was defined by the presence of any symptom reported between

100 2 to 6 months after initial illness. For participants whose first follow-up visit occurred beyond 6

101 months after initial illness, we analyzed symptom presence within the 2-6m PASC

102 ascertainment window.

103 Information on the type and number of SARS-CoV-2 vaccinations were collected at baseline

104 and updated with each interview. Fully vaccinated participants were defined as having received

105 a complete primary vaccine series at least 14 days prior to study enrollment.

106 *Virology*

107 Details of sample collection, RNA extraction, and assay methodology have been reported 108 previously (16). In short, acute viral RNA levels in nasal specimens were assessed using 109 quantitative real time reverse transcription polymerase chain reaction (PCR) using the 110 KingFisher platform to target nucleocapsid (N) and envelope (E) gene regions. A SARS-CoV-2 111 RNA-positive result was defined as having any level of RNA-positivity in N and E gene regions. 112 Presence of infectious virus (infectivity) was measured via cytopathic effect (CPE) in Vero-113 hACE2-TMPRSS2 cells. Infectious viral titers were assessed using conventional plaque assay. 114 All samples were tested by the same two researchers (MGK and MT).

- 115 Collected blood specimens were also used to measure nucleocapsid antigen (N-Ag) at all
- 116 available time points.
- 117 *Host immune factors*
- 118 Plasma biomarker measurements were performed using the automated HD-X Simoa platform.
- 119 Analytes included plasma SARS-CoV-2 Spike receptor binding domain (RBD) IgG and the
- 120 following inflammatory markers: IL-6, IL-10, TNF- α , IFN- α , IFN- γ , IP-10, and MCP-1.
- 121 All assays were performed according to the manufacturer's instructions and assay performance
- 122 was consistent with the manufacturer's specifications.
- 123

124 *Statistical Analysis*

- 125 We describe distribution of virologic and host immune factors at baseline and through follow-up 126 among those with PASC compared to those without PASC. Virologic factors included the
- 127 following:
- 128 RNA viral load over time
- 129 Maximum RNA load
- 130 Duration of RNA detection (defined as days from illness onset to last positive PCR)
- 131 RNA decay rates (defined as linear rate of RNA decline from maximum RNA load)
- 132 Infectious viral titer on day of max RNA
- 133 Duration of detection of culturable virus (defined at days from illness onset to last 134 positive CPE)
- 135 N antigen levels
- 136 N antigen decay rates (defined as linear rate of N antigen decline).

137 Non-infectious and infectious viral shedding and viral load from PCR of nasal specimens were 138 compared using logistic regression followed by marginal effects to calculate adjusted risk ratios 139 (aRR) (17). Subgroup analyses were conducted on participants with available blood specimens 140 and included N antigen and host immune factors. Missing data among the subgroup was 141 assessed and managed using multivariate imputation by chained equations (18). After 142 imputation, we fit linear models using generalized estimating equations with a working 143 independence correlation matrix, identity linkage, and Gaussian distribution using terms for 144 PASC, time period, and interaction between them. The distribution and magnitude of difference 145 of each analyte are summarized graphically. 146 Given the nonlinear presentation of viral load and antibody results we opted to log transform 147 results for comparison. For antibody analysis we further restricted our model to unvaccinated 148 participants in order to compare antibody responses. Study data was captured using REDCap 149 electronic data capture tools. All estimates were calculated using Stata (version 16.1;

150 StataCorp, College Station, TX).

151 *Human Subjects*

152 The study was reviewed by the University of California, San Francisco (UCSF) Institutional

153 Review Board and given a designation of public health surveillance according to federal

154 regulations as summarized in 45 CFR 46.102(d)(1)(2). Informed consent was obtained from all

155 participants. This activity was reviewed by CDC and was conducted consistent with applicable

156 federal law and CDC policy*

157

158 *see e.g., 45 C.F.R. part 46.102(I)(2), 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44 U.S.C. §3501 159 et seq..

160 **Results**

161 *Study participants*

162 From September 2020 to May 2022, we enrolled 136 SARS-CoV-2 infected participants during 163 the acute phase of their illness. Among these participants, 104 completed at least one post-164 acute visit and contributed at least one nasal sample for infectious viral and RNA testing (87% 165 of participants with 10 or more nasal specimens). These participants were all enrolled during 166 their first confirmed case of COVID-19. Among these 104, 80 participants also contributed 167 blood for viral N-antigen and inflammatory marker testing.

168 Participants had a median age of 35.5 years (IQR: 27 to 44), and the cohort was diverse in 169 terms of sex and race and ethnicity (Table 1). Participants were generally healthy and most 170 (77%) did not report pre-existing comorbid medical conditions; the most common comorbidities 171 were lung disease (14%), hypertension (10%), and diabetes (5%). The majority of participants 172 (93%) were infected with pre-Omicron strains of SARS-CoV-2 and most (65%) had not received 173 a SARS-CoV-2 vaccine prior to their infection. Over the course of their acute illness, 96 of 104 174 (92%) participants reported presence of at least one symptom with a median of 9 symptoms 175 (IQR: 4 to 13). The most common acute symptoms were fatigue (76%), cough (71%), rhinorrhea 176 (71%), headache (54%), and sore throat (46%). See Supplemental Table 1 for characteristics of 177 the subgroup of participants who had viral N-antigen and cytokine testing. Participants had 178 similar characteristics as those in the overall cohort, except that all participants in the subgroup 179 were infected with a pre-Omicron variant.

180 *Description of PASC*

181 Among 104 SARS-CoV-2 infected participants with a post-acute follow-up visit, 31 (30%) 182 reported new, worsened or persistent symptoms since the time of SARS-CoV-2 infection,

It is made available under a CC-BY-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.07.14.23292649;](https://doi.org/10.1101/2023.07.14.23292649) this version posted July 16, 2023. The copyright holder for this preprint

183 consistent with PASC. We did not identify a difference between those with and without PASC in

- 184 terms of vaccination status (31% vs 36%). All participants with PASC had been symptomatic
- 185 during acute illness with a median of 12 (9 to 14); among those without PASC the median
- 186 number of symptoms in the acute period was 7 (3 to 12).
- 187 Those meeting criteria for PASC reported a median of 2 (IQR: 1 to 6) symptoms during the post-
- 188 acute period 2-6 months after SARS-CoV-2 infection. The most commonly reported PASC

189 symptoms were fatigue (32%), difficulty with concentration/memory (33%), rhinorrhea (29%),

190 cough (29%), and headache (26%).

191 *Associations of virologic factors with PASC*

192 We compared the magnitude, decay rates and duration of RNA and infectious viral shedding

193 and N-antigen levels between participants who did and did not develop PASC (**Table 2**).

194 Compared to those who did not develop PASC, those who developed PASC had higher

195 maximum RNA viral load, infectious viral load, and N-antigen levels (**Table 2**; **Figure 2a**). Viral

196 RNA decay rates did not significantly differ by PASC status, but decay rates of N-antigen levels

197 were faster in the first 9 days after symptom onset among those with PASC than those without

198 PASC (**Figure 2a**).

199 The development of PASC was associated with a higher proportion of RNA positivity ($p = 0.01$) 200 and infectious viral shedding ($p = 0.02$; Figure 3). Furthermore, participants who went on to 201 develop PASC had a higher median number of days of RNA and infectious viral shedding 202 compared with those who did not develop PASC, though these differences did not reach 203 statistical significance (**Table 2**).

204 *Associations of immune responses with PASC*

212 significant trends toward higher initial levels of MCP, IFN- α , and IFN- γ that attenuated over the

- 213 observation period. Overall, there were no strong associations between starting levels or
- 214 trajectories of inflammatory markers during the acute phase and the later development of
- 215 PASC.

216 **Discussion**

217 In this household-based cohort of outpatients followed prospectively from the time of SARS-218 CoV-2 symptom onset through the post-acute period, we identified several early biologic 219 determinants of PASC. Specifically, we found a relationship between early viral dynamics, 220 adaptive immune responses, and the later development of PASC. These findings suggest that 221 an individual's ability to control viral replication and ongoing viral persistence may play an 222 important role in recovery from SARS-CoV-2 infection, and that the dynamics of the immune 223 responses during the acute and early post-acute phase may determine who goes on to 224 experience post-acute symptoms. Our observations also provide additional rationale for the 225 evaluation of early antiviral therapy as one potential target for mitigating the development of 226 PASC.

227 The etiology of PASC remains incompletely understood and there are no specific treatments 228 available beyond symptom management. To date, most biological assessments of PASC have 229 focused on the post-acute phase of infection (4, 6-9, 19-25). Only a few studies have assessed 230 the relationship between biomarkers in the acute phase of SARS-CoV-2 infection and the later 231 development of PASC (12, 13, 26). Such efforts have identified the presence of SARS-CoV-2 232 RNA in blood at the time of diagnosis (26) and prolonged duration of viral shedding from the 233 upper respiratory tract (12) as correlates of PASC. Overall, these efforts to understand the 234 relationship between acute phase biology and post-acute symptomatology have been limited by 235 the considerable challenges related to collecting specimens during the earliest days following 236 COVID-19 symptom onset, and as a result many studies have been limited to individuals 237 hospitalized with COVID-19, who are not representative of most individuals experiencing PASC.

238 Using orthogonal virologic assessments, we observed a relationship between the early viral 239 burden and the development of PASC. Those who went on to develop PASC had higher

240 maximum levels of SARS-CoV-2 RNA, infectious virus, and viral N-antigen protein during acute 241 infection, and demonstrated more rapid decay of N-antigen levels during the first 9 days after 242 symptom onset, suggesting that either higher antigen burden or a more robust immune 243 response in response to that burden are related to the later development of PASC. Furthermore, 244 we found that those who later developed PASC exhibited more prolonged shedding of infectious 245 virus and had a less robust humoral immune response in the first 9 days following infection, 246 potentially related to more sluggish viral clearance. Taken together, these findings suggest that 247 the total amount of virus present, the immunologic response that results in control of that virus, 248 and the efficiency of clearing infectious virus might all drive the development of post-acute 249 symptoms.

250 A number of demographic and clinical risk factors for PASC have been identified. While prior 251 SARS-CoV-2 vaccination appears to be protective against the development of PASC (27), it 252 remains unclear whether antiviral treatment during the acute phase of illness might reduce the 253 incidence of this condition. Two studies suggest a benefit among those meeting criteria for 254 antiviral therapy (28, 29), but other evaluations have not shown an effect (30, 31). Our findings 255 suggest that interventions that alter the magnitude or duration of infectious virus and the 256 associated immune response during the acute phase might have the potential to affect the 257 development of PASC. These might include antivirals (e.g., protease or RNA polymerase 258 inhibitors) to reduce viral replication and/or monoclonal antibodies or therapeutic vaccination to 259 enhance the immune response needed to neutralize the virus. Assessment of the impact of 260 these interventions during the acute phase of infection is warranted, although we note that most 261 of the cohort included in this analysis was enrolled prior to the availability of SARS-CoV-2 262 vaccines and that preexisting immunity related to prior vaccination or infection might alter these 263 mechanisms.

264 Acute COVID-19 is a highly inflammatory condition (10, 11). While prior cross-sectional and 265 longitudinal analyses in the post-acute phase have demonstrated that PASC is associated with 266 differences in markers of immune activation (7-9, 19, 21, 26), we did not identify significant 267 differences in levels of these markers during the acute phase between those who did and did 268 not go on to develop PASC. There are several possible explanations for this. First, our cohort 269 was likely to be more homogeneous in terms of disease severity, with a lower proportion of 270 those with severe enough acute illness to be unable to complete the study's arduous 271 questionnaire and specimen collection schedule and none who were hospitalized, than those 272 included in other studies. Second, the number of individuals developing PASC was relatively 273 small, limiting our statistical power to observe clear differences even when trends were present. 274 Third, it is possible that these differences develop over time during the post-acute phase, in 275 response to ongoing immunologic activity, and for that reason may not be present during the 276 acute and early post-acute timepoints in this analysis.

277 Strengths of our study include the high degree of adherence to the biospecimen collection 278 protocol and the collection of biospecimens in close proximity to initial symptom onset in a 279 cohort of outpatients, who comprise the vast majority of individuals with PASC. The inclusion of 280 a large proportion of individuals from earlier waves of the pandemic, prior to the widespread 281 availability of vaccination, SARS-CoV-2 treatment, or reinfection allowed us to study the natural 282 history of this condition in the absence of these confounding factors. However, this analysis has 283 several limitations. First, due to relatively small cohort size, we were unable to evaluate 284 whether early markers were associated with specific symptomatic phenotypes of PASC, each of 285 which may be driven by different biology. Second, we defined PASC as the presence of any 286 symptom new or worse since SARS-CoV-2 infection present during the post-acute period, 287 without requiring that the same symptom be present during the acute period; it is possible that 288 this could result in misattribution of some unrelated symptoms to SARS-CoV-2 infection. This is

289 mitigated somewhat by specific training for study staff to interrogate for presence of any 290 reported symptom prior to SARS-CoV-2 infection. Third, we applied a relatively broad time 291 window in which PASC could be defined (2 to 6 months), which although consistent with 292 accepted case definitions might be subject to variability by time since infection (either waxing 293 and waning or resolving symptoms). Future assessment of individuals during later timepoints 294 (e.g., 6 months or beyond) following infection may be warranted. Fourth, the current analysis 295 focuses on the binary presence or absence of symptoms and does not include consideration of 296 symptom severity or impact. Such assessment could lead to further insight into whether different 297 viral titers and immune responses can impact the severity of symptoms rather than simply their 298 presence or absence. Finally, although mitigated through use of multiple imputation, missing 299 data from declined blood sample collection could be a source of error.

300 In summary, viral load and timing of antibody development may be important factors in the 301 pathogenesis of PASC. These early biological markers may be part of a larger cascade of 302 events during the earliest days of SARS-CoV-2 infection that warrant consideration in the larger 303 efforts to develop a mechanistic understanding of this condition. Further research during the 304 acute phase of SARS-CoV-2 infection is required to elucidate causal mechanisms of PASC, 305 which can eventually lead to the development of therapeutics to prevent or treat this condition.

306 **References and Notes**

307 1. Bureau NCfHSUSC. Household Pulse Survey, 2022–2023. Long COVID. 2023 308 [Available from: https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm. 309 2. Peluso MJ, Deeks SG. Early clues regarding the pathogenesis of long-COVID. Trends 310 Immunol. 2022;43(4):268-70. 311 3. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms 312 and recommendations. Nat Rev Microbiol. 2023:1-14. 313 4. Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, et al. Persistent circulating 314 SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. Clin Infect Dis. 2022. 315 5. Stein SR, Ramelli SC, Grazioli A, Chung J-Y, Singh M, Yinda CK, et al. SARS-CoV-2 316 infection and persistence in the human body and brain at autopsy. Nature. 2022;612(7941):758- 317 63. 318 6. Peluso MJ, Deeks SG, Mustapic M, Kapogiannis D, Henrich TJ, Lu S, et al. SARS-CoV-319 2 and Mitochondrial Proteins in Neural-Derived Exosomes of COVID-19. Ann Neurol. 2022. 320 7. Peluso MJ, Lu S, Tang AF, Durstenfeld MS, Ho H-E, Goldberg SA, et al. Markers of 321 Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute 322 Respiratory Syndrome Coronavirus 2 Infection. J Infect Dis. 2021. 323 8. Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, et al. 324 Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 325 infection. Nat Immunol. 2022:1-7. 326 9. Schultheiß C, Willscher E, Paschold L, Gottschick C, Klee B, Henkes S-S, et al. The IL-327 1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep
328 Med. 2022;3(6):100663. Med. 2022;3(6):100663. 329 10. Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, et al. Longitudinal 330 analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584(7821):463-9. 331 11. Del Valle DM, Kim-Schulze S, Huang H-H, Beckmann ND, Nirenberg S, Wang B, et al. 332 An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 333 2020;26(10):1636-43. 334 12. Antar AAR, Yu T, Demko ZO, Hu C, Tornheim JA, Blair PW, et al. Long COVID brain fog 335 and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA from the 336 upper respiratory tract during acute infection. medRxiv. 2023. 337 13. Thompson RC, Simons NW, Wilkins L, Cheng E, Del Valle DM, Hoffman GE, et al. 338 Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae. Nat 339 Med. 2022:1-11. 340 14. Kelly JD, Lu S, Anglin K, Garcia-Knight M, Pineda-Ramirez J, Goldberg SA, et al. 341 Magnitude and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-342 CoV-2) Household Transmission: A Longitudinal Cohort Study. Clin Infect Dis. 2022;75(Suppl 343 2):S193-S204. 344 15. Peluso MJ, Kelly JD, Lu S, Goldberg SA, Davidson MC, Mathur S, et al. Persistence, 345 Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-346 CoV-2 Infection: Cohort Description and Approaches for Measurement. Open Forum Infect Dis. 347 2022;9(2):ofab640. 348 16. Garcia-Knight M, Anglin K, Tassetto M, Lu S, Zhang A, Goldberg SA, et al. Infectious 349 viral shedding of SARS-CoV-2 Delta following vaccination: A longitudinal cohort study. PLoS 350 Pathog. 2022;18(9):e1010802. 351 17. Norton EC, Miller MM, Kleinman LC. Computing Adjusted Risk Ratios and Risk 352 Differences in Stata. The Stata Journal. 2013;13(3):492-509. 353 18. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues 354 and guidance for practice. Statistics in Medicine. 2011;30(4):377-99.

355 19. Peluso MJ, Sans HM, Forman CA, Nylander AN, Ho H-E, Lu S, et al. Plasma Markers of 356 Neurologic Injury and Inflammation in People With Self-Reported Neurologic Postacute 357 Sequelae of SARS-CoV-2 Infection. Neurol Neuroimmunol Neuroinflamm. 2022;9(5).

358 20. Durstenfeld MS, Peluso MJ, Kelly JD, Win S, Swaminathan S, Li D, et al. Role of 359 antibodies, inflammatory markers, and echocardiographic findings in postacute cardiopulmonary 360 symptoms after SARS-CoV-2 infection. JCI Insight. 2022;7(10).

361 21. Klein J, Wood J, Jaycox J, Lu P, Dhodapkar RM, Gehlhausen JR, et al. Distinguishing 362 features of Long COVID identified through immune profiling. medRxiv. 2022.

- 363 22. Son K, Jamil R, Chowdhury A, Mukherjee M, Venegas C, Miyasaki K, et al. Circulating 364 anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms. Eur Respir J. 365 2022.
- 366 23. Jia X, Cao S, Lee AS, Manohar M, Sindher SB, Ahuja N, et al. Anti-nucleocapsid 367 antibody levels and pulmonary comorbid conditions are linked to post–COVID-19 syndrome. JCI 368 Insight. 2022;7(13).
- 369 24. Giron LB, Peluso MJ, Ding J, Kenny G, Zilberstein NF, Koshy J, et al. Markers of fungal 370 translocation are elevated during post-acute sequelae of SARS-CoV-2 and induce NF-κB
371 signaling. JCI Insight. 2022;7(18). signaling. JCI Insight. 2022;7(18).
- 372 25. Pretorius E, Venter C, Laubscher GJ, Kotze MJ, Oladejo SO, Watson LR, et al.
- 373 Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in 374 individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC). Cardiovasc Diabetol. 375 2022;21(1):148.
- 376 26. Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. Multiple Early Factors Anticipate 377 Post-Acute COVID-19 Sequelae. Cell. 2022;0(0).
- 378 27. Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat 379 Med. 2022:1-7.

380 28. Xie Y, Choi T, Al-Aly Z. Association of Treatment With Nirmatrelvir and the Risk of Post-381 COVID-19 Condition. JAMA Intern Med. 2023.

- 382 29. Xie Y, Choi T, Al-Aly Z. Molnupiravir and risk of post-acute sequelae of covid-19: cohort 383 study. BMJ. 2023;381:e074572.
- 384 30. Durstenfeld MS, Peluso MJ, Lin F, Peyser ND, Isasi C, Carton TW, et al. Association of 385 nirmatrelvir/ritonavir treatment with Long COVID symptoms in an online cohort of non-
- 386 hospitalized individuals experiencing breakthrough SARS-CoV-2 infection in the omicron era. 387 medRxiv. 2023.
- 388 31. Bajema KL, Berry K, Streja E, Rajeevan N, Li Y, Yan L, et al. Effectiveness of COVID-19 389 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: target trial emulation
- 390 studies with one-month and six-month outcomes. medRxiv. 2022.
- 391

393

394 **Acknowledgements**

395 We are grateful to the study participants. We would like to acknowledge Jeremy Lambert and 396 Quanterix Inc for providing SARS-CoV2 N-antigen and anti-RBD IgG assay kits.

397

398 **Funding**

399 This study was funded by the Centers for Disease Control and Prevention Broad 400 Agency Announcement (contract 75D30120C08009). The National Institute of Allergy 401 and Infectious Diseases also supported JDK during this study (K23 grant number 402 AI146268). These funding sources had no role in the content of the manuscript nor the 403 decision for publication.

404

405

406 **Author contributions**

407 SL, MJP, JDK, SS, and KNM designed the study supported by funding to JDK. SL, 408 MCD, KL, JPR, SAG, JYC, MFC, SP, AM, KA, and JDK collected clinical data and 409 biospecimens. MT, MGK, AZ, DRM, BG, BCY, AC, JWW, and CP were responsible for 410 biospecimen processing and laboratory testing. SL,DVG, and JDK performed and/or 411 interpreted the statistical analysis. SL, MJP, and JDK drafted the initial manuscript and 412 edited the

413 **Competing Interests**

414 No authors report and competing interests.

415 **Data and Material Availability**

416 All data associated with this study are present in the paper. Patient data can only be 417 shared upon request to JDK.

418 **Table 1.** Baseline characteristics of the cohort.

than 2 weeks before enrollment.
^bVariant status was defined by viral sequencing result for 70 (67%) participants and by calendar time for the remaining 34 (33%) participants.

^cAny comorbidity was defined from the following list: history of autoimmune disease, cancer in the past 2 years, diabetes, HIV/AIDS heart disease, hypertension, lung disease, or kidney disease

^dRNA viral load measurements reported as log-transformed copies/mL.

^eAmong participants with a viral measurement, there were 52 (50%) who had maximum infectious viral load assessed.

- 420 **Figure 1.** Flow diagram of participants evaluated for post-acute sequelae of SARS-CoV-2
- 421 infection (PASC) at month 4.
- 422

424 **Table 2.** Association of virologic factors with post-acute sequelae of SARS-CoV-2 infection

425 (PASC) (N=104).

^aRNA viral load measurements were log-transformed copies/mL.
^bAmong 104 participants with a viral measurement, there were 94 (90%) who had maximum infectious viral load assessed.

^cAdjusted risk ratios calculated with delta-method standard errors.

- 428 **Figure 2.** Comparison of N-antigen and IgG Spike antibody levels among those with and
- 429 without post-acute sequelae of SARS-CoV-2 (PASC) over a 28-day period after symptom onset.
- 430 Figure 2a shows N antigen levels. Figure 2b shows IgG Spike antibody levels among
- 431 unvaccinated participants.
- 432 **Figure 2a. Figure 2b.**
- 433

434
435

435 Estimated mean values and 95% confidence intervals are plotted for PASC and non-PASC groups using generalized
436 estimating equations fit with independent correlation, identity linkage, and normal distribution. Asteri

436 estimating equations fit with independent correlation, identity linkage, and normal distribution. Asterisks denote 437 statistically significant ($p<0.05$) distributions at individual time points.

statistically significant (p<0.05) distributions at individual time points.

439 **Figure 3.** Proportion of RNA and infectious viral shedding for each day after symptom onset 440 among those with and without PASC. Figure 3a depicts RNA viral shedding while Figure 3b

441 describes infectious viral shedding over an 18-day period.

Figure 3b. Infectious viral shedding

446 **Figure 4.** Inflammatory marker levels among those with and without post-acute sequelae of 447 SARS-CoV-2 infection (PASC) over a 28-day period after symptom onset.

- 448
449
- 449 Estimated mean values and 95% confidence intervals are plotted for PASC and non-PASC groups using generalized
450 estimating equations fit with independent correlation, identity linkage, and normal distribution. No sta
- 450 estimating equations fit with independent correlation, identity linkage, and normal distribution. No statistically
451 significant differences in estimated values were found when comparing PASC vs. non-PASC at each tim
- significant differences in estimated values were found when comparing PASC vs. non-PASC at each time point.
- 452
- 453

454 **Supplementary Material**

Abbreviations: BMI: body mass index; HS: high school.

^aFully vaccinated was defined as completion of primary vaccination series with 2 week window prior to symptom onset.

^bVariant status was defined by viral sequencing result for 70 (67%) participants and by calendar time for the remaining 34 (33%) participants.

^cAny comorbidity was defined from the following list: history of autoimmune disease, cancer in the past 2 years, diabetes, heart disease, hypertension, lung disease, or kidney disease

456 457

459 **Supplemental Table 2:** Participant characteristics by outcome status, restricted to those who

460 received a blood draw.

^aFully vaccinated was defined as completion of primary vaccination series with 2 week

window prior to symptom onset.
^bVariant status was defined by viral sequencing result for 70 (67%) participants and by calendar time for the remaining 34 (33%) participants.

^cAny comorbidity was defined from the following list: history of autoimmune disease, cancer in the past 2 years, diabetes, heart disease, hypertension, lung disease, or kidney disease